High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS

Proteasome inhibitors (PIs) such as bortezomib constitute an important part of the modern standard therapy for multiple myeloma (MM). In this study, we set out to assess whether proteasome concentration and chymotrypsin-like (ChT-L) activity could serve as potential biomarkers defining the likelihoo...

Descripción completa

Detalles Bibliográficos
Autores principales: Romaniuk, Wioletta, Bolkun, Lukasz, Kalita, Joanna, Galar, Marzenna, Bernatowicz, Malgorzata, Ostrowska, Halina, Kloczko, Janusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097751/
https://www.ncbi.nlm.nih.gov/pubmed/29946907
http://dx.doi.org/10.1007/s00277-018-3393-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097751/
https://www.ncbi.nlm.nih.gov/pubmed/29946907
http://dx.doi.org/10.1007/s00277-018-3393-7

Ejemplares similares